Gland Pharma Ltd - 543245 - Clarification sought from Gland Pharma Ltd
The Exchange has sought clarification from Gland Pharma Ltd on April 20, 2023, with reference to Movement in Volume.The reply is awaited.20-04-2023
20-04-2023
Gland Pharma Ltd - 543245 - Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended March 31, 2023
Certificate pursuant to Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 202314-04-2023
Gland Pharma Ltd - 543245 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyGland Pharma Ltd 2CIN NO.L24239TG1978PLC002276 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: P Sampath Kumar Designation: Company Secretary and Compliance officer EmailId: sampath@glandpharma.com Name of the Chief Financial Officer: Ravi Shekhar Mitra Designation: Chief Financial Officer EmailId: ravi.mitra@glandpharma.com Date: 12/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.12-04-2023
Gland Pharma Ltd - 543245 - Compliance Certificate As Per Regulation 7(3) Of SEBI (LODR) Regulations,2015 For The Year Ended 31St March 2023.
Compliance Certificate as per Regulation 7(3) of SEBI (LODR) Regulations,2015 for the year ended 31st March 2023.11-04-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Recommendation for Appointment of Statutory Auditors of the Company29-03-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Allotment of 10,600 Equity shares under ESOP29-03-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor Meeting21-03-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor Meeting17-03-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Investor Meetings13-03-2023